PubMed

Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis.

van der Hage JA, Mieog JS, van de Vijver MJ, van de Velde CJ; European Organization for Research and Treatment of Cancer.

Breast Cancer Res. 2007;9(5):R70.PMID: 17931406 [PubMed - indexed for MEDLINE]Related articlesFree article

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B; International Breast Cancer Study Group.

J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81.PMID: 17077359 [PubMed - indexed for MEDLINE]Related articlesFree article

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. Epub 2008 May 17.PMID: 18488249 [PubMed - indexed for MEDLINE]Related articles

Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17.

J Clin Oncol. 2007 May 20;25(15):2006-11. Epub 2007 Apr 23.PMID: 17452676 [PubMed - indexed for MEDLINE]Related articles

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.PMID: 18668363 [PubMed - indexed for MEDLINE]Related articles

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM.

J Clin Oncol. 2003 May 15;21(10):1973-9.PMID: 12743151 [PubMed - indexed for MEDLINE]Related articles

Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W; Korean Breast Cancer Society.

J Clin Oncol. 2007 Jun 10;25(17):2360-8. Epub 2007 May 21.PMID: 17515570 [PubMed - indexed for MEDLINE]Related articles

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.

J Clin Oncol. 2007 Oct 20;25(30):4772-8. Epub 2007 Sep 17.PMID: 17876012 [PubMed - indexed for MEDLINE]Related articles

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A.

J Clin Oncol. 2000 Feb;18(3):584-90.PMID: 10653873 [PubMed - indexed for MEDLINE]Related articles

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.PMID: 11208880 [PubMed - indexed for MEDLINE]Related articlesFree article

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

J Clin Oncol. 2007 Oct 1;25(28):4423-30.PMID: 17906205 [PubMed - indexed for MEDLINE]Related articles

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.

Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ.

J Clin Oncol. 1998 Feb;16(2):470-9.PMID: 9469330 [PubMed - indexed for MEDLINE]Related articles

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L.

Ann Oncol. 2007 May;18(5):874-80. Epub 2007 Feb 10.PMID: 17293601 [PubMed - indexed for MEDLINE]Related articlesFree article

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.PMID: 17636399 [PubMed - indexed for MEDLINE]Related articles

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2007 Sep 1;25(25):3846-52. Epub 2007 Aug 6.PMID: 17679725 [PubMed - indexed for MEDLINE]Related articles

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.

Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M.

J Clin Oncol. 2005 Oct 20;23(30):7512-7.PMID: 16234518 [PubMed - indexed for MEDLINE]Related articles

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Breast Cancer Res Treat. 2009 Aug;116(3):491-500. Epub 2008 Oct 25.PMID: 18953651 [PubMed - indexed for MEDLINE]Related articles

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.

Fisher B, Jeong JH, Anderson S, Wolmark N.

J Natl Cancer Inst. 2004 Dec 15;96(24):1823-31.PMID: 15601638 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of metastatic estrogen receptor and progesterone receptor status on survival.

Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S.

Breast Cancer Res Treat. 2005 Mar;90(1):65-70.PMID: 15770528 [PubMed - indexed for MEDLINE]Related articles

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2008 Mar 20;26(9):1404-10.PMID: 18349391 [PubMed - indexed for MEDLINE]Related articles